Angiochem, Inc. a clinical-stage biotechnology company third world country drugs that are uniquely capable of junction the blood-brain barrier to treat brain diseases, announced today that clinical data for its lead drug candidate, ANG1005, for the care of brain cancers, as well as data showing how compounds from Angiochem’s Engineered Peptide Compounds (EPiC) scaffold are capable of intersection the blood-brain barrier will be highlighted at the Society for Neuroscience Annual Meeting in Chicago on October 17-21, 2009.

More: - Read the rest here